209 related articles for article (PubMed ID: 34117114)
1. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
[TBL] [Abstract][Full Text] [Related]
3. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.
Lum LG; Thakur A; Al-Kadhimi Z; Colvin GA; Cummings FJ; Legare RD; Dizon DS; Kouttab N; Maizel A; Colaiace W; Liu Q; Rathore R
Clin Cancer Res; 2015 May; 21(10):2305-14. PubMed ID: 25688159
[TBL] [Abstract][Full Text] [Related]
4. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
5. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
6. Immune T cells can transfer and boost anti-breast cancer immunity.
Thakur A; Rathore R; Kondadasula SV; Uberti JP; Ratanatharathorn V; Lum LG
Oncoimmunology; 2018; 7(12):e1500672. PubMed ID: 30524893
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
8. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
9. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
12. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibodies for Triple Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
15. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields A; Cheung NK; Lum LG
Res Sq; 2023 Nov; ():. PubMed ID: 37986911
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
[TBL] [Abstract][Full Text] [Related]
17. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS; Luis IV; Macrae E; Sohl J; Litsas G; Winer EP; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2014 Jan; 12(1):71-80. PubMed ID: 24453294
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.
Liu H; Bai L; Huang L; Ning N; Li L; Li Y; Dong X; Du Q; Xia M; Chen Y; Zhao L; Li Y; Meng Q; Wang J; Duan Y; Ming J; Yuan AQ; Yang XP
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599021
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
Bachelot T; Filleron T; Bieche I; Arnedos M; Campone M; Dalenc F; Coussy F; Sablin MP; Debled M; Lefeuvre-Plesse C; Goncalves A; Reynier MM; Jacot W; You B; Barthelemy P; Verret B; Isambert N; Tchiknavorian X; Levy C; Thery JC; L'Haridon T; Ferrero JM; Mege A; Del Piano F; Rouleau E; Tran-Dien A; Adam J; Lusque A; Jimenez M; Jacquet A; Garberis I; Andre F
Nat Med; 2021 Feb; 27(2):250-255. PubMed ID: 33462450
[TBL] [Abstract][Full Text] [Related]
20. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
